How do TPO-R agonists impact the daily lives of chronic ITP patients? Lessons from long-term studies

19th Congress of the European Hematology Association (EHA 19)

12 - 15 Jun 2014

Sorry, this item is currently unavailable.

Published: 4 Sep 2014

Rating:

Save

Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany

Prof Giagounidis presents his talk "How do TPO-R agonists impact the daily lives of chronic idiopathic thrombocytopenic purpura patients? Lessons from long-term studies" at EHA 2014.

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the Chairs & speakers and provided input into the symposium agenda/content.

Related Videos

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

20 Dec 2024

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

28 Oct 2024

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

28 Oct 2024

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

15 Sep 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$